{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,7]],"date-time":"2026-10-07T16:12:30Z","timestamp":1791389550791,"version":"4.3.3"},"reference-count":40,"publisher":"Springer Science and Business Media LLC","issue":"7","license":[{"start":{"date-parts":[[2024,7,5]],"date-time":"2024-07-05T00:00:00Z","timestamp":1720137600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2024,7,5]],"date-time":"2024-07-05T00:00:00Z","timestamp":1720137600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"funder":[{"name":"Hiranis Pharmaceuticals, Karachi, Pakistan","award":["NA"],"award-info":[{"award-number":["NA"]}]},{"name":"Hiranis Pharmaceuticals, Karachi, Pakistan","award":["NA"],"award-info":[{"award-number":["NA"]}]},{"name":"Sihat Sahulat Program, Pakistan","award":["NA"],"award-info":[{"award-number":["NA"]}]},{"name":"Sihat Sahulat Program, Pakistan","award":["NA"],"award-info":[{"award-number":["NA"]}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Arch Dermatol Res"],"DOI":"10.1007\/s00403-024-03203-w","type":"journal-article","created":{"date-parts":[[2024,7,5]],"date-time":"2024-07-05T11:01:58Z","timestamp":1720177318000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":8,"title":["Comparison of efficacy and safety of tofacitinib and azathioprine in patients with alopecia areata and variants: a double-blind, randomized controlled trial"],"prefix":"10.1007","volume":"316","author":[{"given":"Majid","family":"Paracha","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Muhammad","family":"Wasim","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sahibzada M.","family":"Noor","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Abdul Q.","family":"Khan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Farah","family":"Sagheer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Iftikhar","family":"Ahmad","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2024,7,5]]},"reference":[{"key":"3203_CR1","doi-asserted-by":"publisher","first-page":"17011","DOI":"10.1038\/nrdp.2017.11","volume":"3","author":"CH Pratt","year":"2017","unstructured":"Pratt CH, King LE, Messenger AG et al (2017) Alopecia Areata. Nat Reviews Disease Primers 3:17011","journal-title":"Nat Reviews Disease Primers"},{"issue":"4","key":"3203_CR2","doi-asserted-by":"publisher","first-page":"806","DOI":"10.1016\/j.jaad.2016.04.035","volume":"75","author":"LY Liu","year":"2016","unstructured":"Liu LY, King BA, Craiglow BG (2016) Health-related quality of life (HRQoL) among patients with alopecia areata (AA): a systematic review. J Am Acad Dermatol 75(4):806\u2013812e3","journal-title":"J Am Acad Dermatol"},{"issue":"3","key":"3203_CR3","doi-asserted-by":"publisher","first-page":"556","DOI":"10.1016\/j.jaad.2018.01.048","volume":"79","author":"LY Liu","year":"2018","unstructured":"Liu LY, King BA, Craiglow BG (2018) Alopecia Areata is associated with impaired health-related quality of life: a survey of affected adults and children and their families. J Am Acad Dermatol 79(3):556\u2013558e1","journal-title":"J Am Acad Dermatol"},{"key":"3203_CR4","doi-asserted-by":"publisher","first-page":"76","DOI":"10.1186\/s41687-020-00240-7","volume":"4","author":"NVJ Aldhouse","year":"2020","unstructured":"Aldhouse NVJ, Kitchen H, Knight S et al (2020) You lose your hair, what\u2019s the big deal?\u2019 I was so embarrassed, I was so self-conscious, I was so depressed: a qualitative interview study to understand the psychosocial burden of Alopecia Areata. J Patient-Reported Outcomes 4:76","journal-title":"J Patient-Reported Outcomes"},{"issue":"7302","key":"3203_CR5","doi-asserted-by":"publisher","first-page":"113","DOI":"10.1038\/nature09114","volume":"466","author":"L Petukhova","year":"2010","unstructured":"Petukhova L, Duvic M, Hordinsky M et al (2010) Genome-wide association study in Alopecia Areata implicates both innate and adaptive immunity. Nature 466(7302):113\u2013117","journal-title":"Nature"},{"issue":"8","key":"3203_CR6","doi-asserted-by":"publisher","first-page":"2019","DOI":"10.1172\/JCI31942","volume":"117","author":"A Gilhar","year":"2007","unstructured":"Gilhar A, Paus R, Kalish RS (2007) Lymphocytes, neuropeptides, and genes involved in Alopecia Areata. J Clin Invest 117(8):2019\u20132027","journal-title":"J Clin Invest"},{"issue":"9","key":"3203_CR7","doi-asserted-by":"publisher","first-page":"1043","DOI":"10.1038\/nm.3645","volume":"20","author":"L Xing","year":"2014","unstructured":"Xing L, Dai Z, Jabbari A et al (2014) Alopecia Areata is driven by cytotoxic T lymphocytes and is reversed by JAK inhibition. Nat Med 20(9):1043\u20131049","journal-title":"Nat Med"},{"issue":"5","key":"3203_CR8","doi-asserted-by":"publisher","first-page":"e13053","DOI":"10.1111\/dth.13053","volume":"32","author":"AB de Oliveira","year":"2019","unstructured":"de Oliveira AB, Alpalh\u00e3o M, Filipe P, Maia-Silva J (2019) The role of Janus kinase inhibitors in the treatment of Alopecia Areata: a systematic review. Dermatol Ther 32(5):e13053","journal-title":"Dermatol Ther"},{"issue":"4","key":"3203_CR9","doi-asserted-by":"publisher","first-page":"736","DOI":"10.1016\/j.jaad.2016.12.005","volume":"76","author":"W Damsky","year":"2017","unstructured":"Damsky W, King BA (2017) JAK inhibitors in dermatology: the promise of a new drug class. J Am Acad Dermatol 76(4):736\u2013744","journal-title":"J Am Acad Dermatol"},{"issue":"2","key":"3203_CR10","doi-asserted-by":"publisher","first-page":"379","DOI":"10.1016\/j.jaad.2021.03.050","volume":"85","author":"B King","year":"2021","unstructured":"King B, Guttman-Yassky E, Peeva E et al (2021) A phase 2a randomized, placebo-controlled study to evaluate the efficacy and safety of the oral Janus kinase inhibitors ritlecitinib and brepocitinib in Alopecia Areata: 24-week results. J Am Acad Dermatol 85(2):379\u2013387","journal-title":"J Am Acad Dermatol"},{"key":"3203_CR11","unstructured":"European Medicines Agency (2022) Summary of product characteristics: Olumiant (baricitinib) film-coated tablets. http:\/\/www.ema.europa.eu\/"},{"key":"3203_CR12","unstructured":"(2023) Eli Lilly and Company. OLUMIANT (baricitinib): US prescribing information. http:\/\/pi.lilly.com\/us\/zyprexa-pi.pdf. (2023)Accessed: November 2023"},{"key":"3203_CR13","unstructured":"(2023) LITFULO\u2122 (ritlecitinib) capsules, for oral use. https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2023\/215830s000lbl.pdf. (2023)Accessed"},{"key":"3203_CR14","doi-asserted-by":"crossref","unstructured":"Blair HA (2023) Ritlecitinib: first approval. Drugs 1315\u20131321","DOI":"10.1007\/s40265-023-01928-y"},{"key":"3203_CR15","doi-asserted-by":"publisher","first-page":"153","DOI":"10.1186\/s13075-023-03108-5","volume":"25","author":"PJ Mease","year":"2023","unstructured":"Mease PJ, Orbai AM, FitzGerald O et al (2023) Efficacy of tofacitinib on enthesitis in patients with active psoriatic arthritis: analysis of pooled data from two phase 3 studies. Arthritis Res Therapy 25:153","journal-title":"Arthritis Res Therapy"},{"issue":"24","key":"3203_CR16","first-page":"2120","volume":"69","author":"K Traynor","year":"2012","unstructured":"Traynor K (2012) FDA approves tofacitinib for rheumatoid arthritis. Am J Health-System Pharm 69(24):2120","journal-title":"Am J Health-System Pharm"},{"issue":"18","key":"3203_CR17","doi-asserted-by":"publisher","first-page":"1723","DOI":"10.1056\/NEJMoa1606910","volume":"376","author":"WJ Sandborn","year":"2017","unstructured":"Sandborn WJ, Su C, Sands BE et al (2017) Tofacitinib as induction and maintenance therapy for Ulcerative Colitis. N Engl J Med 376(18):1723\u20131736","journal-title":"N Engl J Med"},{"issue":"8","key":"3203_CR18","doi-asserted-by":"publisher","first-page":"1004","DOI":"10.1136\/annrheumdis-2020-219601","volume":"80","author":"A Deodhar","year":"2021","unstructured":"Deodhar A, Sliwinska-Stanczyk P, Xu H et al (2021) Tofacitinib for the treatment of ankylosing spondylitis: a phase III, randomised, double-blind, placebo-controlled study. Ann Rheum Dis 80(8):1004\u20131013","journal-title":"Ann Rheum Dis"},{"issue":"10315","key":"3203_CR19","doi-asserted-by":"publisher","first-page":"1984","DOI":"10.1016\/S0140-6736(21)01255-1","volume":"398","author":"N Ruperto","year":"2021","unstructured":"Ruperto N, Brunner HI, Synoverska O et al (2021) Tofacitinib in juvenile idiopathic arthritis: a double-blind, placebo-controlled, withdrawal phase 3 randomised trial. Lancet 398(10315):1984\u20131996","journal-title":"Lancet"},{"issue":"12","key":"3203_CR20","doi-asserted-by":"publisher","first-page":"2988","DOI":"10.1038\/jid.2014.260","volume":"134","author":"BG Craiglow","year":"2014","unstructured":"Craiglow BG, King BA (2014) Killing two birds with one stone: oral tofacitinib reverses alopecia universalis in a patient with plaque psoriasis. J Invest Dermatology 134(12):2988\u20132990","journal-title":"J Invest Dermatology"},{"issue":"2","key":"3203_CR21","doi-asserted-by":"publisher","first-page":"130","DOI":"10.1159\/000494613","volume":"235","author":"N Almutairi","year":"2019","unstructured":"Almutairi N, Nour TM, Hussain NH (2019) Janus kinase inhibitors for the treatment of severe Alopecia Areata: an open-label comparative study. Dermatology 235(2):130\u2013136","journal-title":"Dermatology"},{"issue":"1","key":"3203_CR22","doi-asserted-by":"publisher","first-page":"22","DOI":"10.1016\/j.jaad.2016.09.007","volume":"76","author":"LY Liu","year":"2017","unstructured":"Liu LY, Craiglow BG, Dai F, King BA (2017) Tofacitinib for the treatment of severe alopecia areata and variants: a study of 90 patients. J Am Acad Dermatol 76(1):22\u201328","journal-title":"J Am Acad Dermatol"},{"issue":"15","key":"3203_CR23","first-page":"e89776","volume":"1","author":"MK Crispin","year":"2016","unstructured":"Crispin MK, Ko JM, Craiglow BG et al (2016) Safety and efficacy of the JAK inhibitor tofacitinib citrate in patients with Alopecia Areata. JCI Insight 1(15):e89776","journal-title":"JCI Insight"},{"issue":"6","key":"3203_CR24","doi-asserted-by":"publisher","first-page":"666","DOI":"10.1684\/ejd.2019.3667","volume":"29","author":"N Enzan","year":"2019","unstructured":"Enzan N, Kitadate A, Yoshioka M et al (2019) Cutaneous involvement of diffuse large B-cell lymphoma incidentally diagnosed based on random skin biopsy of normal-appearing skin. Eur J Dermatology 29(6):666\u2013667","journal-title":"Eur J Dermatology"},{"key":"3203_CR25","doi-asserted-by":"publisher","first-page":"891434","DOI":"10.3389\/fmed.2022.891434","volume":"9","author":"W Zhang","year":"2022","unstructured":"Zhang W, Li X, Chen B et al (2022) Oral Tofacitinib and systemic corticosteroids, alone or in combination, in patients with moderate-to-severe Alopecia Areata: a retrospective study. Front Med 9:891434","journal-title":"Front Med"},{"issue":"1","key":"3203_CR26","first-page":"41","volume":"99","author":"JW Shin","year":"2018","unstructured":"Shin JW, Huh CH, Kim MW et al (2018) Comparison of the treatment outcome of oral tofacitinib with other conventional therapies in refractory alopecia totalis and universalis: a retrospective study. Acta Dermato-Venereologica 99(1):41\u201346","journal-title":"Acta Dermato-Venereologica"},{"issue":"6","key":"3203_CR27","first-page":"12","volume":"12","author":"S Hogan","year":"2019","unstructured":"Hogan S, Wang S, Ibrahim O et al (2019) Long-term treatment with tofacitinib in severe alopecia areata: an update. J Clin Aesthetic Dermatology 12(6):12\u201314","journal-title":"J Clin Aesthetic Dermatology"},{"issue":"5","key":"3203_CR28","doi-asserted-by":"publisher","first-page":"1228","DOI":"10.1016\/j.jaad.2019.10.058","volume":"82","author":"KLS Kerkemeyer","year":"2020","unstructured":"Kerkemeyer KLS, John JM, Sinclair R, Bhoyrul B (2020) Response of Alopecia Areata of the beard to oral tofacitinib. J Am Acad Dermatol 82(5):1228\u20131230","journal-title":"J Am Acad Dermatol"},{"issue":"5","key":"3203_CR29","doi-asserted-by":"publisher","first-page":"978","DOI":"10.1016\/j.jaad.2017.06.027","volume":"77","author":"HS Park","year":"2017","unstructured":"Park HS, Kim MW, Lee JS et al (2017) Oral tofacitinib monotherapy in Korean patients with refractory moderate-to-severe Alopecia Areata: a case series. J Am Acad Dermatol 77(5):978\u2013980","journal-title":"J Am Acad Dermatol"},{"issue":"7","key":"3203_CR30","doi-asserted-by":"publisher","first-page":"1539","DOI":"10.1016\/j.jid.2018.01.032","volume":"138","author":"A Jabbari","year":"2018","unstructured":"Jabbari A, Sansaricq F, Cerise J et al (2018) An open-label pilot study to evaluate the efficacy of Tofacitinib in moderate to severe Patch-Type Alopecia Areata, Totalis, and Universalis. J Invest Dermatology 138(7):1539\u20131545","journal-title":"J Invest Dermatology"},{"issue":"2","key":"3203_CR31","doi-asserted-by":"publisher","first-page":"327","DOI":"10.1016\/j.jaad.2014.03.030","volume":"71","author":"R Sidbury","year":"2014","unstructured":"Sidbury R, Davis DM, Cohen DE et al (2014) Guidelines of care for the management of atopic dermatitis: Sect.\u00a03. Management and treatment with phototherapy and systemic agents. J Am Acad Dermatol 71(2):327\u2013349","journal-title":"J Am Acad Dermatol"},{"issue":"4","key":"3203_CR32","doi-asserted-by":"publisher","first-page":"474","DOI":"10.1001\/archdermatol.2011.79","volume":"147","author":"ME Schram","year":"1950","unstructured":"Schram ME, Borgonjen RJ, Cathelijne; et al (1950) Off-label use of azathioprine in Dermatology a systematic review. Archives Dermatology Dermatol 147(4):474\u2013488","journal-title":"Archives Dermatology Dermatol"},{"issue":"6","key":"3203_CR33","doi-asserted-by":"publisher","first-page":"1123","DOI":"10.1111\/j.1365-2133.2004.06323.x","volume":"151","author":"AV Anstey","year":"2004","unstructured":"Anstey AV, Wakelin S, Reynolds NJ (2004) Guidelines for prescribing azathioprine in dermatology. Br J Dermatol 151(6):1123\u20131132","journal-title":"Br J Dermatol"},{"issue":"3","key":"3203_CR34","doi-asserted-by":"publisher","first-page":"440","DOI":"10.1016\/j.jaad.2003.09.032","volume":"51","author":"J Shapiro","year":"2004","unstructured":"Shapiro J, Canfield D, Duvic M et al (2004) Alopecia Areata investigational assessment guidelines e part II. J Am Acad Dermatol 51(3):440\u2013447","journal-title":"J Am Acad Dermatol"},{"issue":"6","key":"3203_CR35","doi-asserted-by":"publisher","first-page":"600","DOI":"10.1001\/jamadermatol.2017.0001","volume":"153","author":"O Ibrahim","year":"2017","unstructured":"Ibrahim O, Bayart CB, Hogan S et al (2017) Treatment of Alopecia Areata with tofacitinib. JAMA Dermatology 153(6):600\u2013602","journal-title":"JAMA Dermatology"},{"issue":"2","key":"3203_CR36","first-page":"215","volume":"29","author":"HA Shaikh","year":"2019","unstructured":"Shaikh HA, Ur Rehman F, Kiayani AJ (2019) Efficacy and safety of azathioprine in Alopecia Areata. J Pakistan Association Dermatologists 29(2):215\u2013219","journal-title":"J Pakistan Association Dermatologists"},{"key":"3203_CR37","doi-asserted-by":"publisher","unstructured":"Hordinsky M, Hebert AA, Gooderham M et al (2023) Efficacy and safety of ritlecitinib in adolescents with Alopecia Areata: results from the ALLEGRO phase 2b\/3 randomized, double-blind, placebo-controlled trial. Pediatr Dermatol 1\u20137. https:\/\/doi.org\/10.1111\/pde.15378","DOI":"10.1111\/pde.15378"},{"issue":"1","key":"3203_CR38","doi-asserted-by":"publisher","first-page":"29","DOI":"10.1016\/j.jaad.2016.09.006","volume":"76","author":"BG Craiglow","year":"2017","unstructured":"Craiglow BG, Liu LY, King BA (2017) Tofacitinib for the treatment of Alopecia Areata and variants in adolescents. J Am Acad Dermatol 76(1):29\u201332","journal-title":"J Am Acad Dermatol"},{"issue":"2","key":"3203_CR39","first-page":"132","volume":"53","author":"VCS Cua","year":"2019","unstructured":"Cua VCS, Villena JPDS, Lizarondo FPJ, Yap-Silva C (2019) Azathiopine for the treatment of extensive forms of Alopecia Areata: a systematic review. Acta Med Philippina 53(2):132\u2013141","journal-title":"Acta Med Philippina"},{"issue":"10","key":"3203_CR40","doi-asserted-by":"publisher","first-page":"1188","DOI":"10.1111\/j.1365-4632.2010.04576.x","volume":"49","author":"S Farshi","year":"2010","unstructured":"Farshi S, Mansouri P, Safar F, Khiabanloo SR (2010) Could azathioprine be considered as a therapeutic alternative in the treatment of Alopecia Areata? A pilot study. Int J Dermatol 49(10):1188\u20131193","journal-title":"Int J Dermatol"}],"container-title":["Archives of Dermatological Research"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00403-024-03203-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00403-024-03203-w\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00403-024-03203-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,9,9]],"date-time":"2024-09-09T20:38:40Z","timestamp":1725914320000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00403-024-03203-w"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,7,5]]},"references-count":40,"journal-issue":{"issue":"7","published-online":{"date-parts":[[2024,9]]}},"alternative-id":["3203"],"URL":"https:\/\/doi.org\/10.1007\/s00403-024-03203-w","relation":{},"ISSN":["1432-069X"],"issn-type":[{"value":"1432-069X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,7,5]]},"assertion":[{"value":"29 April 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"21 June 2024","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"23 June 2024","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"5 July 2024","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors declare no conflict of construct.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}},{"value":"The Institutional Review Board of Medical Teaching Institute-Lady Reading Hospital (MTI-LRH), Peshawar, Pakistan reviewed and approved the study protocol, under the Reference No. 458\/LRH\/MTI dated 10-08-2023.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical statement"}}],"article-number":"458"}}